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Abstract  
Background. Non alcoholic fatty liver disease (NAFLD), insulin resistance (IR) and obesity 
frequently co-exist with type 2 diabetes but it is uncertain whether these risk factors for 
vascular disease contribute to a change in atherosclerosis over time, independently of 
diabetes status. We tested whether the combination of fatty liver, IR and obesity was 
associated with an increase in coronary artery calcium (CAC) score over time, independently 
of diabetes status, other cardiovascular risk factors and medications. 
Methods. Data were analysed from a South Korean occupational cohort of 2175 people. The 
outcome was increase in cardiac computed tomography (CT) CAC score between baseline 
and follow up. IR was defined by HOMA-IR≥75th centile and fatty liver by ultrasound. Hazard 
ratios (HR) [95% confidence intervals (CIs)] were estimated using Cox proportional hazards 
regression. 
Results. There were 592 (27.2%) participants in whom CAC score increased from baseline 
(mean±SD age at baseline 44.8±5.5 years) and 1583 subjects in whom CAC did not change 
or improved during follow up (mean±SD age 41.6±5.6 years). Diabetes, HOMA-IR, fatty liver 
and obesity prevalence were all higher (all p<0.001), in participants in whom CAC score 
increased from baseline. Adjusting for diabetes and potential confounders, the combination of 
IR, obesity and fatty liver was independently associated with increase in CAC score over time 
[(HR 2.46, (95%CIs 1.50,4.03)]. 
Conclusions. The combination of fatty liver, IR and obesity is associated with progression of 
atherosclerosis over time independently of diabetes, cardiovascular risk factors, and all 
medications for cardiovascular disease and diabetes. 
 
  
Introduction 
Coronary artery calcium (CAC) scoring with cardiac computed tomography (CT) is a sensitive 
method to demonstrate the presence of early atherosclerosis and the use of CAC scores may 
improve CV risk prediction in asymptomatic individuals (1). The total volume of coronary artery 
calcium (CAC) deposits is a good indicator of overall plaque burden and of future coronary 
events. Therefore, CAC scores can be used as a marker of atherosclerotic disease and of 
cardiovascular risk. Although, localization of CAC does not correlate well with the severity or 
vulnerability of coronary lesions, particularly in older patients (2), estimation of the CAC score 
provides a useful non-invasive tool to assess risk of cardiovascular events (3). CAC scores 
also perform better in identifying high-risk individuals compared with an alternative non-
invasive measurement, carotid intima-media thickness, CAC scans are associated with 
relatively low radiation exposure (0.9-1.1 mSv), and CAC scores provide information that can 
be used not only for risk stratification but also can be used to track the progression of 
atherosclerosis (4). 
 
A recent meta-analysis of 49 studies with ultrasound and liver histology shows that ultrasound 
is an accurate, reliable imaging technique for the detection of fatty liver, as compared with 
histology, with a pooled sensitivity of 84.8%, a pooled specificity of 93.6% for detecting ≥20%-
30% steatosis (5). Previously we have investigated relationships between fatty liver diagnosed 
by ultrasound, insulin resistance (IR) and obesity and the presence of CAC (6) in a cross 
sectional analysis of a large Korean cohort. These data showed that whereas fatty liver and 
IR were both independently associated with CAC, obesity was not (6). Several prospective 
studies have reported an increased incidence of cardiovascular events in people with non-
alcoholic fatty liver disease (NAFLD) (7-18) but is still unclear whether NAFLD contributes 
independently to coronary artery plaque progression or whether NAFLD is simply a risk marker 
that co-exists with other recognised cardiovascular (CVD) risk factors such as type 2 diabetes 
(19, 20).  IR co-exists very frequently with type 2 diabetes, obesity and NAFLD (21), and IR 
has been shown to be associated with coronary artery calcium (CAC) (22)  in cross sectional 
analysis, but it is uncertain whether IR also contributes to CAC progression over time, 
independently of diabetes, obesity and fatty liver. 
 
Using data from an occupational cohort in Korea who had measurements of fatty liver and 
CAC score at baseline and who also had a repeat CAC score measured at follow up; we have 
investigated the relationship between fatty liver, IR and obesity with change in CAC score over 
time. Specifically, we tested whether the combination of fatty liver, IR and obesity was 
associated with an increase in coronary artery calcium (CAC) score (as a marker of early 
atherosclerosis) over time, independently of diabetes status, and other cardiovascular risk 
factors and medications used to treat cardiovascular risk factors, cardiovascular disease and 
diabetes. 
 
 
  
Research Design and Methods 
The study population consisted of individuals who had a comprehensive health examination 
and underwent coronary CT scanning to establish a CAC score in 2010 to 2012 and who were 
followed up in 2013 at Kangbuk Samsung Hospital, College of Medicine, Sungkyunkwan 
University in South Korea. For the purpose of this study an increase in CAC over time was 
defined as an increase in a subject’s follow up CAC score, compared with their baseline CAC 
score.  Initially 2623 participants were included and 379 individuals were excluded from the 
study if data were missing for key variables. 44 and 52 subjects were excluded due to past 
history of cancer and cardiovascular disease with some people meeting more than one 
exclusion criterion). Subsequently, data for the remaining 2175 participants were analyzed. In 
South Korea, employees are required to participate in annual or biennial health examinations 
by the Industrial Safety and Health Law.  Some people pay for examinations themselves and 
in other instances employers pay for these health evaluations. The institutional review board 
at Kangbuk Samsung Hospital has approved the study, and no specific informed consent was 
considered necessary.  
 
Body mass index (BMI) was calculated as weight in kilograms divided by height in meters 
squared. Obesity was defined in this Asian population as BMI >25 kg/m2. Blood samples were 
collected after an overnight fast. Waist circumference was measured according to a 
standardized operating procedure. Briefly, the mid-point between the lowest rib and the 
superior iliac crest was identified in the mid-axilliary line. At this point a measuring tape (SECA 
200, circumference measuring tape) was placed around the abdomen, ensuring that the tape 
was horizontal to the floor. A measurement was taken to the nearest 0.1 cm, at the end of a 
normal expiration. If the two readings varied by more than 1%, there was a computer-
generated prompt to take a third reading. Questionnaires were used to ascertain information 
regarding alcohol consumption (g/day), smoking (never, ex, current), and frequency of 
moderate activity each week. Moderate activity was defined as more than 30 min activity per 
day that induced slight breathlessness. An enzymatic calorimetric test was used to measure 
total cholesterol (TC) and triglyceride (TG) concentrations. The selective inhibition method 
was used to measure HDL-C, and a homogeneous enzymatic calorimetric method was used 
to measure the concentration of LDL-C (Advia 1650 Autoanalyzer, Bayer Diagnostics, 
Leverkusen, Germany). Metabolic syndrome (MetS was defined by the 2009 joint interim 
statement of the International Diabetes Federation Task Force on Epidemiology and 
Prevention criteria, with waist circumference thresholds of ≥90cm for men and ≥80cm for 
women that are specific for Asian populations (23) .  
 
Questionnaires were used to ascertain information regarding alcohol consumption, smoking 
(never, ex, current), and frequency of moderate activity each week (defined as more than 30 
min activity per day that induced slight breathlessness). Hypertension (HTN) was defined by 
self report, medication for hypertension or systolic blood pressure ≥ 140 mm Hg or diastolic 
blood pressure ≥ 90 mm Hg, or self reported medication for hypertension. Diabetes was 
identified by self report, prescription of medication for diabetes, fasting glucose ≥126mg/dl or 
HbA1C≥6.5%. The homeostasis model assessment of IR (HOMA-IR) index was calculated by 
the following equation: HOMA-IR = (fasting insulin [mIU/mL] * fasting glucose [mmol/L])/22.5. 
Since there are no population-specific thresholds to define IR in a Korean population, we 
stratified the populations using the 75th percentile to establish an IR group (HOMA-IR ≥75th 
percentile), as described previously in this population (6, 21) and as recommended by the 
European Group for the Study of Insulin Resistance (24). BMI≥25kg/m2 was used to define 
overweight/obesity. Abdominal ultrasonography (Logic Q700 MR; General Electric, 
Milwaukee,WI) using a 3.5-MHz probe was performed in all subjects by experienced clinical 
radiologists, and fatty liver was diagnosed based on standard criteria, including hepatorenal 
echo contrast, liver brightness, and vascular blurring (25) . All computed tomography scans 
were obtained with a Lightspeed VCT XTe-64 slice MDCT scanner (GE Healthcare, Tokyo, 
Japan) with the same standard scanning protocol using 2.5-mm section collimation, 400 ms 
rotation time, 120 kV tube voltage, and 124 mAS (310 mA*0.4 second) tube current under 
ECG-gated dose modulation.The quantitative CAC scores were calculated according to the 
method described by Agatston et al (26) .  
 
Statistical analysis 
Statistical analyses were performed with Stata version 11.2 (StataCorp LP, College Station, 
Texas). All reported p values are 2-tailed, and comparisons with p < 0.05 were considered 
statistically significant. Continuous variables were expressed as mean(SD) for normally 
distributed variables or median (interquartile range) if not normally distributed.  
Categorical variables were expressed as percentages and compared between groups 
using the chi-squared test. Cox proportional hazards models were used to estimate hazard 
ratios (HRs and 95% confidence intervals for CAC>0 change over time. We checked the 
proportional hazards assumption by examining graphs of estimated log (-log) CAC>0 
change. HRs and 95% CIs were estimated for each individual risk factor from a multivariable 
model containing all risk factors. The models were adjusted for age and sex (model 1); age, 
sex center, year, alcohol consumption, smoking, exercise, education, diabetes status, 
hypertension, medication for lipid, medication for hypertension, medication for diabetes and 
LDL-C concentration (model 2); age, sex center, year, alcohol consumption, smoking, 
exercise, education, diabetes status, hypertension, medication for lipid, medication for 
hypertension, medication for diabetes, LDL-C concentration, eGFR and hsCRP 
concentration at baseline. Models were adjusted to test the independence of associations 
with the study outcome (increase in CAC score over time) and IR, fatty liver and obesity as 
single risk factors, combinations of any two of these three risk factors, and all three of these 
risk factors combined. 
 
  
Results 
 
A total of 2,175 subjects had CAC on baseline and follow-up scans performed 
approximately 2.3±0.6 years apart. Their mean age was 42.5 years, and 95.1% were men. 
Mean CAC scores were : 19.2(± 79.6) at baseline and 29.5(± 111.6) at follow-up.  
During the median 2.3-year follow-up period, 592 subjects (27.2%) had an increased CAC 
score at follow-up examination compared with baseline. Table 1 shows the characteristics of 
the subjects in whom CAC increased from baseline during the follow up period, compared with 
1583 subjects in whom CAC score was unchanged or improved during follow up. The age of 
subjects in whom CAC score increased during follow-up was 44.8±5.5 years and the age of 
subjects in whom CAC did not change or improved during follow up was 41.6±5.6 years 
(means±SDs). The proportion of people with diabetes, fatty liver and obesity were all higher 
in people with a CAC score that increased over time (all p<0.001) at 15.0%, 61.7%; and 56.9%, 
respectively, compared with 6.3%; 49.0%; and 45.4% among people whose CAC score did 
not change or improved over time. HOMA-IR was also higher in subjects in whom CAC 
increased compared to subjects in whom CAC score did not increase, or improved, from 
baseline (1.51 (0.97,2.36) (median, 95%CIs) versus 1.28 (0.82,1.90) (median, 95%CIs) 
(p<0.001). 
 
Table 2 shows the baseline characteristics of the cohort by HOMA-IR quartile. Age was 
remarkably similar in each quartile and differed by <1 year between quartile group. The 
proportion of people with diabetes, obesity, fatty liver and MetS differed between quartiles, and 
in the highest quartile of HOMA-IR, fatty liver was present in 82.8%, obesity was present in 
77.7% and diabetes was present in 21.0% of participants. Table 3 shows the numbers (%) of 
subjects with an improvement in CAC score between baseline and follow up, no change in 
CAC score between baseline and follow up, and an increase in CAC score between baseline 
and follow up, according to HOMA-IR quartiles. 
 
Table 4 shows the associations between individual key risk factors and increase in 
CAC score at follow up. IR (HOMA-IR quartile 4) was associated with increase in CAC score 
after adjusting for other risk factors (HR 1.79 (95%CIs 1.09, 2.95)). There were similar trends 
for the associations between an increase in CAC score over time and obesity, fatty liver and 
diabetes (HR 1.37 (95%Cis 0.96, 1.96) and (HR 1.28 (95%CIs 0.91, 1.80), 1.72 (0.91-3.22)]. 
respectively). Table 5 shows the associations between obesity, IR and fatty liver with an 
increase in CAC score during follow-up. Table 5 also shows associations for these exposures 
and an increase in CAC score during follow-up, when the factors were present in combinations 
of two risk factors, and for all three risk factors combined.  Adjusting for diabetes status and 
all other covariates and potential confounders for an increase in CAC score, including age, 
sex, Center of study, year of study, alcohol consumption, smoking, exercise, education, 
hypertension, CVD, medication for hypertension, medications for diabetes, lipid lowering 
medications, LDL-C concentration, eGFR and hsCRP concentration at baseline; the 
combination of IR, obesity and fatty liver was associated with an increase in CAC score over 
time [(HR 2.46, (95%CIs 1.50,4.03)]. 
Among study subjects with baseline CAC = 0, the incidence of CAC>0  increased 
according to HOMA- IR quartiles. We conducted same analysis for table 4,5 using a cutoff 
point of 10 in CAC change, the results showed very similar tendency. (supplementary table 
1,2). 
 
Discussion 
Our data show for the first time that the combination of fatty liver, IR and obesity is associated 
with progression of atherosclerosis during a median of 2.3 years follow-up in an occupational 
cohort whose median age was 42.0 years. This association was independent of diabetes 
status, lipid lowering medications (including statins), treatments for diabetes, and all measured 
cardiovascular risk factors including LDL-C concentration, eGFR and hsCRP concentration at 
baseline.  
 
The proportions of people with diabetes, fatty liver, obesity, and the HOMA-IR values were all 
higher in people in whom CAC score increased during follow-up. However, adjustment for age, 
sex, diabetes, and other covariates and potential confounders for CVD, had little impact on 
the strength of the association for the combination of IR, obesity and fatty liver and increase 
in CAC score over time. We have previously shown in this cohort in a prospective study, that 
combining fatty liver, IR and obesity was associated with a very marked (~14 fold) increase in 
the risk of incident diabetes, during five years of follow up (21) . Although we have now shown 
that the combination of fatty liver, IR and obesity is associated with a comparatively smaller 
(~2.4 fold) increase in the risk of progression of CAC score over time, the presented data show 
that these three risk factors (fatty liver, IR and obesity) combined, are associated with a much 
greater hazard for CAC progression over time, than any single one of these three risk factors 
in isolation (Table 4). Fatty liver, insulin resistance and obesity all frequently cluster together 
in people with type 2 diabetes; and our data shows convincingly that fatty liver, IR and obesity 
combined are associated with an increased HR for CAC score over time, even after adjusting 
for diabetes status.  
 
CAC progression over time is associated with future cardiovascular events (27, 28) and CAC 
progression predicts all cause mortality (29). Diabetes is strongly associated with all-cause 
mortality amongst persons with extensive CAC (30), and we have shown in this cohort that 
fatty liver, IR and obesity occur in over 50% of people who develop diabetes (21). Since these 
three risk factors occur so frequently with diabetes, and diabetes is a strong risk factor for 
developing CAC, it has been uncertain to date whether the cluster of fatty liver, IR and obesity 
risk factors are associated with increased risk of CAC progression over time, independently of 
diabetes status. We adjusted our multivariable regression models not only for diabetes status, 
but also for LDL-C concentration and for all lipid lowering treatments, since it is known that 
statins can promote coronary artery plaque regression (specific data for statin medication 
alone was not available). Interestingly, it has been recently suggested that statins may stabilize 
coronary artery plaque by promoting coronary atheroma calcification, independent of their 
plaque-regressive effects (31), thus it is plausible that in subjects taking statins specifically, an 
increase in CAC may represent a stabilization of the plaque, rather than an increase in 
atheroma within an increasing coronary artery plaque burden. 
 
The association between NAFLD and multiple complex metabolic and pro-inflammatory 
changes that have an effect on the vasculature (19, 20), mean that it is difficult to identify 
causality in assessing the relationship between fatty, IR, obesity and increase in CAC score 
over time. It is plausible that a predisposition towards fatty liver (and IR) with obesity and 
progression of the liver disease per se, (with increasing inflammation and fibrosis), could 
further worsen IR and inflammation and thereby increase cardiovascular disease risk. Non 
alcoholic steatohepatitis (NASH) is a more severe form of NAFLD and NASH is more strongly 
associated with cardiovascular disease and IR than simple steatosis (9, 32, 33). The hepatic 
inflammation that occurs with NASH is marked by macrophage activation (34)  and it is 
possible that vascular inflammation and CAC is also more marked with NASH (and increased 
IR), compared to simple steatosis. Consequently, it seems plausible that altered liver fat 
metabolism and an inflammatory state in NASH are the important factors contributing to 
vascular disease in subjects who have the combination of fatty liver, IR and obesity.  
 
There are a few limitations of our study. There was a relatively short period of follow-up, 
subjects were relatively young and most men mostly men) and there is not data on waist 
circumference and some secondary causes of chronic liver diseases (e.g., viral hepatitis 
markers). There were relatively few subjects who experienced an increase in CAC score >10 
during follow up and therefore there was limited power to show independent associations 
between risk factors and an increase in CAC score >10. However, that said the results of these 
analyses were consistent with the data showing associations between risk factors and any 
increase in CAC score. Coefficients of variation for measurement of fatty liver and CAC within 
this cohort are not available. Fatty liver was assessed by liver ultrasound and ultrasonography 
has limited sensitivity, being unable to detect liver fat infiltration that is approximately <30% by 
liver weight. Ultrasonography was performed by experienced clinical radiologists who 
diagnosed fatty liver based on known standard clinical criteria that included hepatorenal echo 
contrast, liver brightness, and vascular blurring.  We are therefore unable to include evidence 
of agreement between radiologists. However, in the presented analyses we used the clinical 
definition of fatty liver as a dichotomous exposure variable. It is unlikely that fatty liver status, 
IR or obesity would have been influenced by CAC score and consequently any random 
misclassification bias of fatty liver status would also bias our findings for the relationship 
between the combination of fatty liver, IR obesity with CAC progression, towards the null. With 
regard to fatty liver, we are also unable to comment on NAFLD severity as histological 
assessment of liver using the Kleiner score (35)  (which is the gold standard for assessing 
hepatic inflammation and fibrosis), was not performed. Consequently, we are unable to 
examine whether the more severe forms of NAFLD such as NASH with fibrosis are associated 
with CAC progression over time. There is no established definition of IR as a categorical 
variable and we have used ≥75th centile of HOMA-IR to define IR, as we have described 
before in this cohort (6). Each of the individual risk factors i.e. obesity, IR and fatty liver was 
associated with an increased risk of increase in CAC score, albeit there was limited power to 
prove that each of these individual risk factors was independently associated with increase in 
CAC score. For all three risk factors combined there was a greater cumulative risk conveyed 
by all three factors combined. Consequently, we were able to show a significant effect of all 
three risk factors combined, despite the limited power of the study. 
 
In summary, we have shown that the combination of fatty liver, IR and obesity is associated 
with progression of atherosclerosis (as indicated by increase in CAC score over time) and 
this association was independent of diabetes status, lipid lowering and antihypertensive 
medications and all measured cardiovascular risk factors.  Advice on effective approaches to 
primary prevention of cardiovascular disease should be offered to individuals with these risk 
factor patterns.  
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Table 1. Baseline characteristics of study participants by change in CAC score at follow up 
 
Characteristics 
Overall CAC change 
P value 
No CAC change or improvement in 
CAC   CAC increased from baseline 
Number 2,175 1,583 592  
Age (years)a 42.5 (5.7) 41.6 (5.6) 44.8 (5.5) <0.001 
Male (%) 95.1 93.6 99.2 <0.001 
Seoul center (%) 53.0 51.3 57.6 0.009 
BMI (kg/m2) a 25.1 (3.0) 24.9 (3.0) 25.8 (3.0) <0.001 
Obesity (%) 48.5 45.4 56.9 <0.001 
Current smoker (%) 33.9 33.2 35.6 0.288 
Alcohol intake (%)b 34.6 32.3 40.7 <0.001 
High education level (%)c 85.9 85.5 87.0 0.404 
Diabetes (%) 8.6 6.3 15.0 <0.001 
Hypertension (%) 24.0 20.3 33.6 <0.001 
Medication for dyslipidemia (%)  5.4 4.0 9.0 <0.001 
Medication of Diabetes (%) 3.6 2.4 6.8 <0.001 
Medication of Hypertension (%) 11.2 8.1 19.6 <0.001 
Systolic BP (mmHg) a 119.2 (12.2) 118.5 (12.2) 121.3 (11.9) <0.001 
Diastolic BP (mmHg)a 76.5 (9.5) 75.9 (9.4) 78.1 (9.5) <0.001 
Glucose (mg/dL)a 100.1 (17.5) 98.6 (15.4) 103.9 (21.9) <0.001 
Total cholesterol (mg/dL)a 210.0 (37.2) 206.8 (36.4) 218.6 (38.0) <0.001 
LDL-C (mg/dL)a 133.0 (33.5) 130.0 (32.7) 141.1 (34.2) <0.001 
HDL-C (mg/dL)a 51.0 (12.1) 51.7 (12.4) 49.3 (11.1) <0.001 
Triglycerides (mg/dL)d 137 (94-197) 130 (89-190) 153 (110.5-215) <0.001 
ALT (U/l)d 25 (18-38) 25 (18-37) 28 (20-40) <0.001 
GTP (U/l)d 36 (23-56) 34 (22-54) 40 (27-65) <0.001 
HOMA-IR d 1.34 (0.86-2.01) 1.28 (0.82-1.90) 1.51 (0.97-2.36) <0.001 
Fatty liver (%) 52.5 49.0 61.7 <0.001 
MetS (%) 26.3 22.2 36.1 <0.001 
eGFR mls/min a 90.8 (13.8) 91.1 (13.4) 90.2 (14.7) 0.184 
eGFR<90 mls/min (%) 55.6 55.1 57.1 0.401 
eGFR<60 mls/min (%) 
 
hsCRP (mg/dL) 
0.28 
 
0.06 (0.04-0.12) 
 
0.19 
 
0.06(0.03-0.11) 
0.51 
 
0.07(0.04-0.13) 
0.228 
 
0.022 
CAC score  a 72.7 (141.7) 33.2 (71.4) 81.3 (151.5) <0.001 
CAC score d 22 (6-74) 8 (3-21) 27 (8-81) <0.001 
Data are ameans (standard deviation), dmedians (interquartile range), or percentages. Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; BP, blood 
pressure; HDL-C, high-density lipoprotein-cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance,  b ≥20 g/day; c ≥ College graduate. 
 
CAC score  a   mean  of cac  score if cac>0 
CAC score d   median  of cac  score if cac>0… 
 
  
Table 2. Baseline characteristics of study participants by HOMA-IR quartiles  
 
Characteristics 
 HOMA-IR quartiles 
P for trend 
Overall Q1 Q2 Q3 Q4 
Number              2,175 544 544 544 543  
Age (years)a 42.5 (5.7) 42.7 (6.0) 42.9 (5.6) 42.2 (5.8) 42.1 (5.4) 0.014 
Male (%) 95.1 93.8 94.7 94.9 97.1 0.016 
Seoul center (%) 53.0 56.3 52.4 54.6 48.8 0.036 
BMI(kg/m2) 25.1(3.0) 23.1(2.3) 24.4(2.4) 25.6 (2.4) 27.3 (3.1) <0.001 
Obesity (%) 48.5 19.3 37.7 59.4 77.7 <0.001 
Current smoker (%) 32.3 30.9 29.0 34.4 35.0 0.049 
Alcohol intake (%)b 34.6 33.5 33.6 34.2 37.2 0.197 
High education level (%)c 85.9 85.5 86.5 86.9 84.8 0.788 
Diabetes (%) 8.6 2.4 4.8 6.4 21.0 <0.001 
Hypertension (%) 24.0 14.5 20.0 27.2 34.1 <0.001 
Medication of dyslipidemia 5.4 3.3 4.4 6.3 7.6 0.001 
Medication of Diabetes 3.6 0.7 2.2 2.6 8.8 <0.001 
Medication of Hypertension 11.2 6.1 9.6 14.0 15.3 <0.001 
Systolic BP (mmHg) a 119.2 (12.2) 114.8 (11.1) 118.2 (11.9) 120.4 (12.1) 123.6 (12.0) <0.001 
Diastolic BP (mmHg)a 76.5 (9.5) 73.4 (8.8) 75.5 (9.2) 77.2 (9.2) 79.9 (9.5) <0.001 
Glucose (mg/dL)a 100.1 (17.5) 91.4 (8.7) 97.2 (10.4) 99.8 (11.4) 111.8 (26.4) <0.001 
Total cholesterol (mg/dL)a 210.0 (37.2) 203.7 (36.6) 209.5 (36.9) 211.8 (36.3) 215.0 (38.2) <0.001 
LDL-C (mg/dL)a 133.0 (33.5) 128.5 (34.4) 133.4 (33.6) 134.6 (32.1) 135.6 (33.5) <0.001 
HDL-C (mg/dL)a 51.0 (12.1) 56.9 (13.4) 51.2 (11.9) 49.1 (10.8) 46.0 (9.4) <0.001 
Triglycerides (mg/dL)d 137 (94-197) 95.5 (70-129.5) 129 (93.5-179) 156.5 (107-222) 183 (133-259) <0.001 
ALT (U/l)d 25 (18-38) 20 (15-27) 23 (17-32) 27 (20-40) 35 (25-50) <0.001 
GTP (U/l)d 36 (23-56) 25 (18-40) 32 (21-50) 39 (27-59.5) 48 (33-74) <0.001 
Fatty liver (%) 52.5 25.4 42.0 59.7 82.8 <0.001 
MetS (%) 26.3 6.2 13.3 31.0 58.1 <0.001 
eGFR mls/min a 90.8 (13.8) 90.1 (13.2) 89.8 (13.8) 91.4 (12.9) 91.9 (15.0) 0.008 
eGFR<90 mls/min (%) 55.6 57.7 58.8 54.0 51.9 0.020 
eGFR<60 mls/min (%) 0.28 0.00 0.74 0.37 0.00 0.716 
hsCRP (mg/dL) 
CAC score (if >0) a 
0.06(0.04-0.12) 
72.7(141.7) 
0.05(0.02-0.09) 
73.7(147.7) 
0.05(0.03-0.1) 
53.4(87.6) 
0.06(0.04-0.12) 
84.5(163.5) 
0.08(0.05-0.15) 
75.8(148.8) 
<0.001 
0.579 
CAC score (if >0) d 22(6-74) 20(7-68) 22(5-64) 17(5-89) 24(6-75) 0.579 
Data are ameans (standard deviation), dmedians (interquartile range), or percentages. Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; BP, blood 
pressure; HDL-C, high-density lipoprotein-cholesterol; b ≥20 g/day; c ≥ College graduate. 
 
  
Table 3. Distribution of change in CAC score over time according to quartiles of HOMA-IR 
 
 
 
 
 
 
 
 
 
 
 
 
HOMA-IR Quartiles 1 (Q1)   ~0.856, Q2 0.858-1.337, Q3 1.338-2.007, Q4 2.008~ 
 
 
 
  
 HOMA IR 
 Q1 
 (N=544) 
Q2 
 (N=544) 
Q3 
 (N=544) 
Q4 
 (N=543) 
 N (%) N (%) N (%) N (%) 
CAC  score improved 18 (3.3) 20 (3.7) 27 (5.0) 19 (3.5) 
No change in CAC score 
CAC increased 
412 (75.7) 
114 (21.0) 
387 (71.1) 
137 (25.2) 
373 (68.6) 
144 (26.4) 
327 (60.2) 
197 (36.3) 
Table 4 Hazard ratios for an increase in CAC score over time for risk factors at baseline identified from a multi-variable model 
 
 HR [95%CIs] 
Age (per year) 1.11 [1.08, 1.15] 
Male sex 18.35 [4.25, 79.23] 
Center 1 
Year of study 1.05 [0.77, 1.43] 
Alcohol=0 g/day 1.00 (reference) 
>0~20 g/day 0.62 [0.35, 1.09] 
>=20 g/day 0.68 [0.38, 1.22] 
Never smoking 1.00 (reference) 
Ex-smoking 0.85 [0.58-1.24] 
Smoking 0.92 [0.62-1.36] 
Exercise 1.40 [0.91-2.14] 
Education status 0.94 [0.56-1.58] 
Diabetes 1.72 [0.91-3.22] 
Hypertension 1.15 [0.74-1.80] 
Medication for dyslipidemia 1.23 [0.71-2.14] 
Medication for Diabetes 0.84 [0.35-2.04] 
Medication for Hypertension 1.30 [0.73-2.30] 
Fatty liver 1.28 [0.91-1.80] 
Obesity 1.37 [0.96-1.96] 
HOMA   Q1 1.00 (reference) 
Q2 1.45 [0.94-2.23] 
Q3 1.05 [0.66-1.69] 
Q4 1.79 [1.09-2.95] 
hsCRP 
eGFR 
1.14 [0.80-1.62] 
1.01[1.00-1.02] 
 
  
Table 5. Associations between obesity, insulin resistance, fatty liver and increase in CAC score during follow up 
  HR [95%CIs] 
Total Number with 
CAC score 
increase/number 
with risk factor(s) 
(%) 
 
Model 1 
 
Model 2 
 
Model 3 
NONE OF 
3 
FACTORS 
89/403 (22.1) 1 1 1 
IR ALONE 11/26 (42.3) 2.60(1.09-
6.19) 
1.54(0.55-
4.34) 
1.70(0.59-
4.91) 
OBESITY 
ALONE 
16/76 (21.1) 1.24(0.66-
2.35) 
1.31(0.66-
2.61) 
1.36(0.67-
2.76) 
FATTY 
LIVER 
ALONE 
68/238 (28.6) 1.44(0.98-
2.11) 
1.27(0.83-
1.93) 
1.28(0.83-
1.96) 
IR + 
OBESITY 
9/22 (40.9) 2.91(1.11-
7.58) 
3.14(1.10-
8.96) 
3.35(1.15-
9.72) 
IR + 
FATTY 
LIVER 
21/54 (38.9) 2.60(1.40-
4.82) 
1.65(0.80-
3.37) 
1.62(0.78-
3.34) 
OBESITY 
+ FATTY 
LIVER  
    61/173 (35.3) 1.98(1.31-
2.99) 
1.49(0.93-
2.39) 
1.51(0.93-
2.44) 
IR 
+OBESE 
+FATTY 
LIVER 
66/159 (41.5) 3.04(2.01-
4.62) 
2.35(1.44-
3.84) 
2.46(1.50-
4.03) 
Insulin resistance (IR) = HOMA IR ≥75%.  
MODEL 1 Adjusted for age and sex. MODEL 2 Adjusted for age, sex, center, year, alcohol consumption, smoking, exercise, education, diabetes 
status, hypertension, medication for lipid, medication for hypertension, medication for diabetes , LDL-C concentration. MODEL 3 Adjusted for 
age, sex, center, year, alcohol consumption, smoking, exercise, education, diabetes status, hypertension, medication for lipids, medication for 
hypertension, medication for diabetes , LDL-C concentration, eGFR and hsCRP concentration at baseline 
